Clinuvel (CUV) is held by 5 ASX ETFs. Over the last year it fell 35.6%: on $10,000, −$3556. We explain 8 big moves in that time.
About CUV
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$406.4m
- Held by5 ETFs
- Big moves8 in 1Y
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +2.7%peak +3.6%1 Sep 2026· Operational
Clinuvel's announcement that it is considering a Nasdaq listing and potential ASX delisting spooked ASX investors, triggering a sell-off on elevated volume several days after the news dropped.
- −12.7%peak −18.5%27 Aug 2026· Earnings Miss
Clinuvel's FY26 full-year results disappointed the market, triggering a sharp sell-off despite a decade of profitability headline, as investors reacted negatively to the actual numbers or forward outlook in the annual report and preliminary final report released minutes before the price move.
- +5.8%peak +6.3%18 Aug 2026· Sector Flow
CUV rose sharply as the broader ASX healthcare sector surged strongly on the same day, lifting sector peers including CUV.
- −7.4%2 Apr 2026· Sector Flow
Likely sector-wide decline in Australian shares on April 1, 2026, with no company-specific negative news identified.
- −9.3%27 Feb 2026· Earnings Miss
Clinuvel Pharmaceuticals H1 FY2026 profit declined 26% due to margin compression, disappointing investors despite record revenue.
- +11.9%16 Feb 2026· Unknown
No specific catalyst identified; the article merely lists CLINUVEL as an ASX biotech watchlist firm.
- −6.4%11 Feb 2026· Unknown
Abnormal price drop not explained by available news; likely driven by unannounced factors or sector flow.
- +5.0%19 Dec 2025· Unknown
No specific news was found to explain the 5% price movement; the cause remains unidentified.
Held by 5 ETFs
Of every $10,000 in each fund, how much is in CUV today.
Why did CUV fall 6.4% on 11 Feb 2026?
Clinuvel
Abnormal price drop not explained by available news; likely driven by unannounced factors or sector flow.
The only available news article is a positive analyst recommendation on biotech stocks from the day before, which would not typically cause a 6.37% drop. There are no company-specific announcements or negative catalysts in the provided articles. The move is therefore likely due to unobserved events or broader market dynamics.
Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice. It does not consider your objectives, finances or needs. Past performance is not a guide to future performance.
Evidence
News coverage
What it did to the 5 ETFs holding CUV
On $10,000 in each fund, at the weight it holds today